Document is current

Any future updates will be listed below

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

Crossref DOI link: https://doi.org/10.1186/s13045-016-0338-2

Published Online: 2016-10-12

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark